Therapeutic use of diaminophenothiazines
US-10188658-B2 · Jan 29, 2019 · US
Phenothiazine diaminium salts and their use
US10864216B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10864216-B2 |
| Application number | US-201815912166-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2018 |
| Priority date | Feb 11, 2011 |
| Publication date | Dec 15, 2020 |
| Grant date | Dec 15, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a disease selected from the group consisting of: skin cancer or melanoma; a viral disease; a bacterial disease; and a protozoal disease, the method comprising administering to a subject in need thereof the compound of the following formula: or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 2. The method of claim 1 , wherein the administering is oral. 3. The method of claim 2 , wherein the administering is selected from: (a) about 100 mg of compound, 3 times daily; (b) about 150 mg of compound, 2 times daily; and (c) about 200 mg of compound, 2 times daily. 4. The method of claim 1 , wherein the disease is skin cancer or melanoma. 5. The method of claim 1 , wherein the disease is a viral disease. 6. The method of claim 5 , wherein the viral disease is selected from the list consisting of: Hepatitis C; HIV; and West Nile Virus. 7. The method of claim 1 , wherein the disease is a bacterial disease. 8. The method of claim 1 , wherein the disease is a protozoal disease. 9. The method of claim 7 , wherein the protozoal disease is malaria.
Assignees
Inventors
Classifications
Living organisms or biological materials · CPC title
Visible light · CPC title
- C07D279/20Primary
with hydrogen atoms directly attached to the ring nitrogen atom · CPC title
- A61K31/5415Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10864216B2 cover?
- Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
- Who is the assignee on this patent?
- Wista Lab Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D279/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).